Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2019 May 2;68(10):1641-1649.
doi: 10.1093/cid/ciy760.

Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients

Farnaz Foolad  1 , Samuel L Aitken  1   2 , Terri Lynn Shigle  1 , Amrita Prayag  3 , Shashank Ghantoji  3 , Ella Ariza-Heredia  3 , Roy F Chemaly  3
Affiliations
Comparative Study

Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients

Farnaz Foolad et al. Clin Infect Dis. .

Abstract

Background: The use of oral ribavirin (RBV) for respiratory syncytial virus (RSV) infections is not well studied. With the drastic increase in the cost of aerosolized RBV, we aimed to compare outcomes of hematopoietic cell transplant (HCT) recipients treated with oral or aerosolized RBV for RSV infections.

Methods: We reviewed the records of 124 HCT recipients with RSV infections treated with oral or aerosolized RBV from September 2014 through April 2017. An immunodeficiency scoring index (ISI) was used to classify patients as low, moderate, or high risk for progression to lower respiratory infection (LRI) or death.

Results: Seventy patients (56%) received aerosolized RBV and 54 (44%) oral RBV. Both groups had a 27% rate of progression to LRI (P = 1.00). Mortality rates did not significantly differ between groups (30-day: aerosolized 10%, oral 9%, P = 1.00; 90-day: aerosolized 23%, oral 11%, P = .10). Classification and regression tree analysis identified ISI ≥7 as an independent predictor of 30-day mortality. For patients with ISI ≥7, 30-day mortality was significantly increased overall, yet remained similar between the aerosolized and oral therapy groups (33% for both). After propensity score adjustment, Cox proportional hazards models showed similar mortality rates between oral and aerosolized therapy groups (30-day: hazard ratio [HR], 1.12 [95% confidence interval {CI}, .345-3.65, P = .845).

Conclusions: HCT recipients with RSV infections had similar outcomes when treated with aerosolized or oral RBV. Oral ribavirin may be an effective alternative to aerosolized RBV, with potential significant cost savings.

Keywords: aerosolized ribavirin; hematopoietic cell transplant; oral ribavirin; outcome; respiratory syncytial virus.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan-Meier 30-day survival curve for hematopoietic cell transplant recipients treated with aerosolized or oral ribavirin for respiratory syncytial virus infection (n = 124). Abbreviation: RSV, respiratory syncytial virus.
Figure 2.
Figure 2.
Cumulative incidence function for progression to lower respiratory infection in hematopoietic cell transplant recipients treated with aerosolized or oral ribavirin for upper respiratory syncytial virus infection (n = 52).
See this image and copyright information in PMC

Comment in

References

    1. Falsey AR, Walsh EE. Respiratory syncytial virus infection in adults. Clin Microbiol Rev 2000; 13:371–84. - PMC - PubMed
    1. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplantation. Blood 2011; 117:2755–63. - PubMed
    1. Khanna N, Widmer AF, Decker M, et al. . Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis 2008; 46:402–12. - PubMed
    1. Martino R, Porras RP, Rabella N, et al. . Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant 2005; 11:781–96. - PMC - PubMed
    1. Raboni SM, Nogueira MB, Tsuchiya LR, et al. . Respiratory tract viral infections in bone marrow transplant patients. Transplantation 2003; 76:142–6. - PubMed

Publication types

MeSH terms